Insights Into Breast Cancer 2021
Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer, and attitudes toward recently introduced and upcoming agents in relapsed/refractory disease
Faculty Chair
Mark Pegram, MD
Stanford Women’s Cancer Center, Palo Alto, CA
Faculty Chair
Debu Tripathy, MD
MD Anderson Cancer Center, Houston, TX
Faculty Chair
Adam Brufsky, MD
University of Pittsburgh, Pittsburgh, PA
Faculty Chair
Reshma Mahtani, DO
University of Miami Health System, Deerfield Beach, FL
Faculty Chair
Mark Pegram, MD
Stanford Women’s Cancer Center, Palo Alto, CA
Faculty Chair
Reshma Mahtani, DO
University of Miami Health System, Deerfield Beach, FL
Faculty Chair
Sara Tolaney, MD
Dana-Farber Cancer Institute, Boston, MA
Faculty Chair
William Gradishar, MD, FACP
Center for Women’s Cancer Care, Chicago, IL, USA
Faculty Chair
Hope Rugo, MD
University of California San Francisco, CA
More Information
- Virtual Series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Virtual Series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual Series
- Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Virtual Series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Virtual Series
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
More Information
- Virtual Series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Virtual Series
- Illinois, Iowa, Nebraska, North Dakota, South Dakota, Minnesota, Wisconsin, Michigan, Indiana, Ohio
More Information
- Virtual Series
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of breast cancer
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained:
- HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, chemotherapies
- HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, trastuzumab deruxtecan, tucatinib, neratinib, AIs, chemotherapies
- TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan), immunotherapy, chemotherapies
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors will comprise 10–15 medical oncologists representative of each region
